Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY2784544 in myeloproliferative neoplasms
2011-001012-56Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gandotinib in myeloproliferative disorder (MPD), polycythemia vera (PV), thrombocythemia and 1 more (3 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Objective response rate. Started Jun 2012; status: active.
02
Drugs
gandotinib
03
Conditions
myeloproliferative disorder (MPD)polycythemia vera (PV)thrombocythemiamyelofibrosis (MF)
Beyond the preview
Go deeper on 2011-001012-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001012-56.